Celerion and the Korean Drug Development Fund (KDDF) are collaborating to provide drug development experience and support for South Korea’s emerging drug discovery and development industry. 

Companies funded by KDDF will have access to Celerion’s experience in early clinical research and bioanalysis, as well as the global footprint of external partner sites. The collaboration will support a sharing of knowledge between KDDF and Celerion, and will focus on developing innovative and efficient ways to bring Korean drug discoveries to the global market. The agreement further enhances both organizations’ ability to effectively apply principles of translational medicine to the development of innovative new drugs.

Dongho Lee, M.D., MBA, CEO of KDDF, said, “Together with Celerion, KDDF will be able to provide professional consulting services to the Korean research communities to advance the research activities and promote important innovation.”

Celerion will support all programs with KDDF from the recently announced business expansion within the Biomedical Research Institute at Seoul National University Hospital (SNUH), in South Korea.